MEGF9 prevents lipopolysaccharide-induced cardiac dysfunction through activating AMPK pathway

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Sepsis Pathogenesis

Background:

• Sepsis-induced cardiac dysfunction involves inflammation and oxidative damage.
• The role of Multiple EGF-like domains 9 (MEGF9) in sepsis-related cardiac injury is unknown.

Purpose of the Study:

• To investigate the role and mechanism of MEGF9 in sepsis-induced cardiac injury.
• To explore MEGF9 as a potential therapeutic target for sepsis.

Main Methods:

• MEGF9 expression manipulated using viral vectors in vitro and in vivo.
• Lipopolysaccharide (LPS) used to induce septic injury in cardiomyocytes and mice.
• AMP-activated protein kinase (AMPK) pathway investigated using global AMPK knockout mice.

Main Results:

• LPS stimulation reduced MEGF9 expression in cardiomyocytes and mice.
• Lower plasma MEGF9 levels correlated with cardiac dysfunction in septic patients.
• MEGF9 overexpression attenuated LPS-induced inflammation and cardiac injury, while knockdown aggravated it.
• MEGF9 alleviated cardiac dysfunction by activating the AMPK pathway.

Conclusions:

• MEGF9 protects against LPS-induced inflammation, oxidative damage, and cardiac injury.
• MEGF9 activation of the AMPK pathway is crucial for its protective effects.
• Targeting MEGF9 presents a potential therapeutic strategy for sepsis-induced cardiac dysfunction.